Evidence map›Paper›PMID 38999138›Full record

ArticleMolecules (Basel, Switzerland)2024

Identification of Benzothiazoles Bearing 1,3,4-Thiadiazole as Antiproliferative Hybrids Targeting VEGFR-2 and BRAF Kinase: Design, Synthesis, BIO Evaluation and In Silico Study.

Wafaa A Ewes, Samar S Tawfik, Aya M Almatary, Mashooq Ahmad Bhat, Hamed W El-Shafey, Ahmed A B Mohamed, Abdullah Haikal, Mohammed A El-Magd, Abdullah A Elgazar, Marwa Balaha and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Discovery of thieno[2,3-RSC advances · 2026
    Article
  3. Article
  4. Design, synthesis, andRSC advances · 2024
    Article
  5. Design, Synthesis, Pharmacological Evaluation of Quinazolin-4(3Drug design, development and therapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wafaa A EwesDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0001-7690-2906
Samar S TawfikDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Aya M AlmataryDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt.ORCID 0000-0002-5081-8949
Mashooq Ahmad BhatDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.ORCID 0000-0001-8426-4692
Hamed W El-ShafeyDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0002-7848-8785
Ahmed A B MohamedDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0003-3912-1021
Abdullah HaikalDepartment of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0003-2548-3507
Mohammed A El-MagdDepartment of Anatomy, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.ORCID 0000-0002-3314-9202
Abdullah A ElgazarDepartment of Pharmacognosy, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.ORCID 0000-0002-5851-3306
Marwa BalahaDepartment of Medical, Oral and Biotechnological Sciences, "G. d'Annunzio" University of Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy.ORCID 0000-0001-8042-6009
Abdelrahman HamdiDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0002-0196-1976

Funding

King Saud University, Riyadh, Saudi Arabia. Research supporting project number (RSPD2024R740)
6 · The paper itself

Abstract

Cancer remains a leading cause of death worldwide, often resulting from uncontrolled growth in various organs. Protein kinase inhibitors represent an important class of targeted cancer therapies. Recently, the kinases BRAF and VEGFR-2 have shown synergistic effects on tumor progression. Seeking to develop dual BRAF/VEGFR-2 inhibitors, we synthesized 18 amino-benzothiazole derivatives with structural similarities to reported dual inhibitors. Four compounds-

Indexed as

Antineoplastic AgentsBenzothiazolesCell ProliferationMolecular Docking SimulationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafThiadiazolesVascular Endothelial Growth Factor Receptor-2Cell Line, TumorComputer SimulationDrug DesignDrug Screening Assays, AntitumorHumansMolecular StructureSorafenibStructure-Activity Relationship1,3,4-thiadiazoleAntineoplastic AgentsBenzothiazolesBRAF protein, humanKDR protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafSorafenibThiadiazolesVascular Endothelial Growth Factor Receptor-2antitumor activityapoptosisbenzothiazolesBRAF inhibitioncell cycle analysismolecular dockingVEGFR-2 inhibition

Identifiers

PMID38999138
PMCPMC11243196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.